The macrophage immune checkpoint inhibitor, magrolimab, is a humanized monoclonal antibody against CD47, a cell surface receptor involved in inhibiting tumor-cell phagocytosis by macrophages and dendritic cells [69]. This evidence concerns the gene CD47 and neoplasm.